Código QR (código de barras bidimensional)

Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX)

IntroductionThis Phase I study evaluated the safety and tolerability of concurrent niraparib, an oral poly(ADP-ribose) polymerase (PARP) 1/2 inhibitor, with definitive radiotherapy in women with locally advanced or platinum-sensitive metastatic cervical cancer. Dose escalation followed a Bayesian Op...

ver descrição completa

Na minha lista:
Principais autores: Piyush Pathak, Eunji Jo, Susan Hilsenbeck, Matthew L. Anderson, Alfredo Echeverria, Shelly Sharma, Jan Sunde, Tracilyn Hall, Anthony Costales, Claire Hoppenot, Michelle Ludwig
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2026-03-01
coleção:Frontiers in Oncology
Assuntos:
brachytherapy
cervix cancer
niraparib
PARP inhibitor
radiotherapy
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2026.1677424/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados